### FORM 7

# **MONTHLY PROGRESS REPORT**

name of CNSX Issuer: ARCH BIOPARTNERS INC. (The Issuer).
Trading Symbol: <u>ACH</u>
Number of Outstanding Listed Securities: 48,260,179 common shares
Date: December 6, 2013
Date. December 6, 2013

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by the CNSX Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the CNSX.ca website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the CNSX Policies. The discussion in this report must be factual, balanced and non-promotional.

#### **General Instructions**

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 Interpretation and General Provisions.

### **Report on Business**

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

Presently, the Issuer does not have any cash flow from operations. The Issuer's business activities have been focused on progressing the Issuer's



main technology development platforms and matters relating to continuous disclosure requirements and corporate governance.

2. Provide a general overview and discussion of the activities of management.

During November, 2013, management continued to build relationships in the business community in which it operates. Management has continued to manage the operations of its four subsidiaries. These subsidiaries are described in the Updated Listing Statement 2A filed on the CNSX website on February 24, 2012 ("Listing Statement").

During the month of November, the Issuer's management has otherwise worked on governance and continuous disclosure requirements.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

The Issuer did not produce or acquire any new products, technologies or services during the month of November, 2013.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

This item is not applicable to the Issuer for the month of November, 2013.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

This item is not applicable to the Issuer for the month of November, 2013 other than what was disclosed in a press release issued to the public and filed with the CNSX on October 21, 2013. The Issuer announced the engagement of M Partners in connection to an intended private placement.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

This item is not applicable to the Issuer for the month of November, 2013.



7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

No acquisitions of the Issuer's assets occurred during November, 2013.

There were no dispositions.

8. Describe the acquisition of new customers or loss of customers.

This item is not applicable as the Issuer has no customers.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

This item is applicable to the Issuer for the month of November, 2013.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

This item is not applicable to the Issuer for the month of November, 2013.

Report on any labour disputes and resolutions of those disputes if applicable.

This item is not applicable to the Issuer.

11. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

This item is not applicable to the Issuer.

12. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

This item is not applicable to the Issuer.



13. Provide details of any securities issued and options or warrants granted.

This item is not applicable to the Issuer for the month of November, 2013.

14. Provide details of any loans to or by Related Persons.

The Issuer was not a party to any new loans to or by any Related Person in November 2013. Details of an existing loan by a Related Person are disclosed in the Listing Statement and the Issuer's annual and quarterly financial statements.

15. Provide details of any changes in directors, officers or committee members.

There were no changes in directors, officers or committee members during November, 2013.

16. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The trends and risks which are likely to impact the Issuer are detailed in Item 17 of the Listing Statement.



## **Certificate Of Compliance**

The undersigned hereby certifies that:

- 1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
- 2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
- 3. The undersigned hereby certifies to CNSX that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).
- 4. All of the information in this Form 7 Monthly Progress Report is true.

Dated:	December 6,	, 2013	

Richard Muruve

Name of Director or Senior

Officer

(Signed) "Richard Muruve"

Signature

**Director and CEO** 

Official Capacity

Issuer Details Name of Issuer	For Month End	Date of Report YY/MM/D
ARCH BIOPARTNERS INC.	November 30, 2013	2013/12/6
Issuer Mailing Address 27 St. Clair Ave East, P.O. Box 305		
City/Province/Postal Code Toronto, Ontario M4T 2M5	Issuer Fax No. 905-770-4454	Issuer Telephone No. 647-428-7031
Contact Name Richard Muruve	Contact Position Director and CEO	Contact Telephone No. 647-428-7031
Contact Email Address info@archbiopartners.com	Web Site Address www.archbiopartners.com	

